The Myeloma Solutions Fund (MSF) provides grants, fellowships, and investments to fund innovative approaches that deliver true impact for patients with high-risk (HR) multiple myeloma (MM), with an emphasis on the t(4;14) subtype. Collaboration is encouraged to help ensure that data generation drives strategies for clinical application with a vision towards cure. Breakthrough and disruptive approaches are prioritized.
Research is needed to find a true or functional cure for MM patients with high-risk MM. Key areas include:
- Understanding mechanisms of drug resistance and progression.
- Using an individual’s specific disease characteristics to target treatment.
- Implementing novel clinical strategies to guide therapeutic decisions and improve outcomes for these patients.
MSF leadership
Michael Robbins
Scientific Advisor
Michael serves as scientific advisor and managing director for the MSF and brings 30 years of experience in biopharma drug discovery and development. For the last 15 years Michael’s research has focused on Multiple Myeloma including leadership roles for research, translational medicine, and medical strategy.
MSF Scientific Advisory Committee
Gareth Morgan, MD, PhD
Larry Boise, PhD
Arun Wiita, MD, PhD
Marta Chesi PhD
NYU Langone Health
Emory Winship Cancer Institute
University of California San Francisco
Mayo Clinic
Committee members serve on a rotating/temporary basis providing ad hoc advice and feedback to overall MSF strategy and programs.
MSF is a donor advised fund administered by Impact Assets. The advisors to the fund are Nick Pritzker, Susan Pritzker, Regan Pritzker, and Chris Olin.